ARWR Latest Headlines

Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target

at www.tipranks.com (Wed, 5-Aug 9:56 AM)

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD)

at www.tipranks.com (Wed, 5-Aug 9:10 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)

at www.tipranks.com (Wed, 5-Aug 9:00 AM)

Analysts’ Top Healthcare Picks: Vera Therapeutics (VERA), Arrowhead Pharmaceuticals (ARWR)

at www.tipranks.com (Wed, 5-Aug 5:00 AM)

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

at www.tipranks.com (Wed, 5-Aug 5:00 AM)

Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating

at www.tipranks.com (Wed, 5-Aug 2:56 AM)

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

at www.tipranks.com (Tue, 4-Aug 10:56 PM)

Arrowhead Pharmaceuticals GAAP EPS of -$1.36 misses by $0.08, revenue of $75.23M beats by $31.22M

at seekingalpha.com (Tue, 4-Aug 4:05 PM)

Here are the major earnings after the close Tuesday

at seekingalpha.com (Tue, 4-Aug 10:00 AM)

Arrowhead Pharmaceuticals Q3 2026 Earnings Preview

at seekingalpha.com (Mon, 3-Aug 5:35 PM)

Arrowhead Pharmaceuticals Announces Fiscal Q3 Results Webcast, Spotlight on Pipeline and Strategic Direction

Market Chameleon (Wed, 22-Jul 11:07 AM)

Plozasiran Achieves Up to 81% Triglyceride Reduction in Arrowhead’s Phase 3 Studies—100% Drop in Acute Pancreatitis for Highest-Risk Patients

Market Chameleon (Wed, 22-Jul 7:51 AM)